Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539819 | 1.00 | TLR7 (0.42) | TLR7TLR8NQO2AAK1PTGER4 | |
| SCHEMBL23037677 | 0.83 | NQO2 (0.39) | NQO2AAK1PTGER4 | |
| SCHEMBL30539833 | 0.83 | NQO2 (0.39) | NQO2AAK1PTGER4 | |
| SCHEMBL23037625 | 0.83 | NLRP3 (0.49) | TLR7TLR8PTGER4GRM2 | |
| SCHEMBL5065092 | 0.81 | TLR8 (0.48) | TLR7TLR8 | |
| SCHEMBL5057090 | 0.81 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL5095445 | 0.79 | CA12 (0.46) | TLR7TLR8 | |
| SCHEMBL5057054 | 0.79 | TLR8 (0.45) | TLR7TLR8 | |
| SCHEMBL23037636 | 0.77 | PDPK1 (0.37) | TLR7TLR8AAK1GRM2 | |
| SCHEMBL5144738 | 0.77 | TLR8 (0.68) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-3784670-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR7 236/4885TLR8 210/4885NQO2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.